||| Menü 
Startseite
Firmenveranstaltungen, Neuemissionen

10/11
09/11
08/11
07/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
03/10
Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

10/11
09/11
03/09
04/09
05/09
06/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
Fusionen, Übernahmen

11/11
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09
09/09
10/09
11/09
Personal, Belegschaft, Meldungen zu Produkten

06/08
07/08
08/08
09/08
10/08
11/08
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09

Datenschutz
Impressum
Bankleitzahlen - online.de


MorphoSys to Present at Two Upcoming Investor Conferences

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced
today that its management will give company presentations at two
upcoming investor conferences.

Deutsche Börse Group - German Equity Forum
Date: Tuesday, November 10, 2009
Time: 03:00 pm CET (02:00 pm GMT, 09:00 am ET)
Venue: Frankfurt/Main, Germany
Presenter: Dave Lemus, CFO of MorphoSys AG

WestLB Germany Conference
Date: Wednesday, November 18, 2009
Time: 12:30 pm CET (11:30 am GMT, 06:30 am ET)
Venue: Frankfurt/Main, Germany
Presenter: Dr. Simon Moroney, CEO of MorphoSys AG


The PDF versions and, if available, live and archived webcasts of the
presentations will be provided at www.morphosys.com.


About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel
antibodies for therapeutic, diagnostic and research applications. The
Company's HuCAL technology is one of the most powerful methods
available for generating fully human antibodies. By successfully
applying this and other proprietary technologies, MorphoSys has
become a leader in the field of therapeutic antibodies, one of the
fastest-growing drug classes in human health-care. Through its
alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The
Company is expanding its drug pipeline by adding new partnered
programs, and by building a portfolio of fully-owned therapeutic
antibodies. For its proprietary portfolio, the Company is focused on
the areas of oncology and inflammation, within which it plans to have
eight active programs by the end of 2009. Its most advanced program
is MOR103, a first-in-class, fully human antibody against GM-CSF.
MorphoSys expects to commence a Phase Ib/IIa trial of this antibody
in rheumatoid arthritis patients in the second half of 2009. Via its
business unit AbD Serotec, MorphoSys is expanding the reach of its
technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock
Exchange under the symbol "MOR". For further information, visit
http://www.morphosys.com/


HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registered
trademarks of MorphoSys AG


This communication contains certain forward-looking statements
concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of
the date of this release and involve risks and uncertainties. Should
actual conditions differ from the Company's assumptions, actual
results and actions may differ from those anticipated. MorphoSys does
not intend to update any of these forward-looking statements as far
as the wording of the relevant press release is concerned.


For more information, please contact MorphoSys:
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
gutjahr-loeser@morphosys.com

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
brkulj@morphosys.com

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
kulpi@morphosys.com


This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.



 
 ||| Themen-Infos 
· Mehr zu dem Thema Contracts & Corporate events & IPOs &

Der meistgelesene Artikel zu dem Thema Contracts & Corporate events & IPOs &:
Change on the Board of Directors of Feintool Holding AG

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht



Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.095 Sekunden